Business Wire

Mitsubishi Heavy Industries to Launch Two New Series of Room Air-Conditioners, Nine Models Specially Designed for the European Market

Del

Mitsubishi Heavy Industries, Ltd. (MHI)(TOKYO:7011) has developed two new series of wall-mounted room air-conditioners for the European market, with production and marketing to commence in October. The new series, the top-of-the-line ZSX Series and the premium ZS Series, comprise of 9 models in total. In addition to their sophisticated air-conditioning functions and energy-saving performance, both series feature a unique design to blend in beautifully with any interior decor.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160919006598/en/

MHI wall-mounted room air-conditioner ZSX Series (Photo: Business Wire)

MHI wall-mounted room air-conditioner ZSX Series (Photo: Business Wire)

The design was created by the Italian industrial design studio Tensa srl, based in Milan, and responds to a broad spectrum of European design demands thanks to its rounded contours and stylish design features. In addition to the nine regular models, two limited-edition color variations are in preparation. Further, computational fluid dynamics (CFD) normally used to design jet engine blades have been adopted to optimize the layout and air duct shape of both the fan and heat exchanger.

Both new series have been engineered to provide significantly improved comfort and energy savings. The adoption of CFD in the design of the fan blade shape has resulted in operating noise of only 19 decibels (dB)(A)1 in “silent” mode. The adoption of MHI’s twin rotary compressor for the ZSX Series, combined with enhanced vector control enabling optimal control of the compressor motor, delivers greater efficiency throughout the range. As a result the ZSX models achieve outstanding energy efficiency receiving Europe’s highest energy rating (EU Energy Label of A+++) in both cooling and heating mode. Furthermore, all models come standard-equipped with motion sensors that detect the level of ambient human movement and automatically control the room temperature as well as the air-conditioner’s ON/OFF operations.

Furthermore, all models feature a “silent” operating mode for the outdoor unit and weekly timer function for greater environmental compatibility and convenience. Also, by connecting them to any commercially available Wi-Fi adapter, operation via smartphones, etc. is possible.

Going forward, MHI will apply its energy saving technologies cultivated in the heat pump field and Europe’s cutting-edge product design, to provide products responding to local market needs, as a way of contributing to the realization of a low-carbon society.

 

Main specifications of top-of-the-line ZSX Series

Indoor unit   SRK20ZSX-S   SRK25ZSX-S   SRK35ZSX-S   SRK50ZSX-S   SRK60ZSX-S
Outdoor unit SRC20ZSX-S SRC25ZSX-S SRC35ZSX-S SRC50ZSX-S SRC60ZSX-S
Cooling   Power (kW) 2.0 2.5 3.5 5.0 6.1
SEER 2 8.50 6.70 6.00
Energy rating A+++ A+++ A+++ A++ A+
Heating Power (kW) 2.7 3.2 4.3 6.0 6.8
Max. power (kW) 5.0 5.4 6.3 7.7 8.2
SCOP 3 5.10 4.60 4.36
Energy rating A+++ A+++ A+++ A++ A+
Dimensions Indoor unit   Height 305mm
Width 920mm
Depth 220mm
Outdoor unit Height 640mm
Width 800mm
    Depth   290mm
 

Main specifications of standard ZS Series

Indoor unit   SRK20ZS-S   SRK25ZS-S   SRK35ZS-S   SRK50ZS-S
Outdoor unit SRC20ZS-S SRC25ZS-S SRC35ZS-S SRC50ZS-S
Cooling   Power (kW) 2.0 2.5 3.5 5.0
SEER 7.8 7.8 7.8 6.3
Energy rating A++ A++ A++ A++
Heating Power (kW) 2.7 3.2 4.0 5.8
Max. power (kW) 4.2 4.4 4.8 6.6
SCOP 4.6 4.6 4.6 4.2
Energy rating A++ A++ A++ A+
Dimensions Indoor unit   Height 290mm
Width 870mm
Depth 230mm
Outdoor unit Height 540mm 595mm
Width 780mm 780mm
    Depth   290mm   290mm
 

Notes:

1

 

A refers to “A-weighting.” A-weighted decibels are measurements that compensate for human perception of sounds.

2

SEER: seasonal energy efficiency ratio

3

SCOP: seasonal coefficient of performance

 

About Mitsubishi Heavy Industries Group

Mitsubishi Heavy Industries, Ltd. (MHI), headquartered in Tokyo, is one of the world’s leading industrial firms with 80,000 group employees and annual consolidated revenues of around 38 billion U.S. dollars. For more than 130 years, the company has channeled big thinking into innovative and integrated solutions that move the world forward. MHI owns a unique business portfolio covering land, sea, sky and even space. MHI delivers innovative and integrated solutions across a wide range of industries from commercial aviation and transportation to power plants and gas turbines, and from machinery and infrastructure to integrated defense and space systems.
For more information, please visit MHI’s website: www.mhi-global.com
For Technology, Trends and Tangents, visit MHI’s new online media SPECTRA: spectra.mhi.com

Contact information

PRESS CONTACT:
Mitsubishi Heavy Industries, Ltd.
Daniel Lochmann, +81-(0)3-6716-2168
PR Director
mhi-pr@mhi.co.jp
Fax: +81-(0)3-6716-5860

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom